Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-blind, Randomised, Multiple Dose, Phase III, Multicentre Study of Alpharadin in the Treatment of Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases

Next Previous
Trial Profile

A Double-blind, Randomised, Multiple Dose, Phase III, Multicentre Study of Alpharadin in the Treatment of Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 31 May 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Radium 223 chloride (Primary)
  • Indications Adenocarcinoma; Bone metastases; Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ALSYMPCA
  • Sponsors Algeta; Bayer

Most Recent Events

  • 25 May 2023 According to a Bayer media release, data from this study will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, June 2-6, 2023.
  • 21 Sep 2020 Results of post-hoc analysis investigating the role of NLR, neutrophilia and lymphopenia on the outcome of mCRPC patients treated with Ra-223 presented at the 45th European Society for Medical Oncology Congress
  • 27 Aug 2020 According to a Bayer media release, Chinese National Medical Products Administration (NMPA) has approved Xofigo(radium-223 dichloride) for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastases. The approval of Xofigo in China is based on the ALSYMPCA data as well as the NCT01810770 trial operated in Asia.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top